Respiratory and sleep medicine
Pulmonary vasculitides and pulmonary haemorrhage
How GPA, MPA, EGPA and anti-GBM disease affect the lung, recognising diffuse alveolar haemorrhage (rising DLCO, bloodier BAL aliquots), interpreting ANCA, induction with glucocorticoids plus rituximab or cyclophosphamide, and mepolizumab or benralizumab for EGPA.
Tier 2Condition
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- Small-vessel vasculitis is the lung's main vasculitis: GPA, MPA, EGPA (the ANCA-associated vasculitides) and anti-GBM disease.
- The respiratory emergency is diffuse alveolar haemorrhage (DAH). Think of it in anyone with new bilateral infiltrates and a falling haemoglobin, with or without haemoptysis.
- Pulmonary-renal syndrome (lung haemorrhage plus glomerulonephritis) is ANCA vasculitis or anti-GBM until proven otherwise. Send ANCA and anti-GBM the same day.
Loading the rest of the note…
Finished reading?
Sources
- Therapeutic Guidelines: Rheumatology (vasculitis)AU/NZTherapeutic Guidelines Ltd, current eTG edition (version not verified)
- Avacopan (Tavneos) PBS listing for severe active GPA and MPAAU/NZPharmaceutical Benefits Scheme, 2024
- 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 2021;73:1366-83American College of Rheumatology (Chung SA et al), 2021
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 2024;83:30-47EULAR (Hellmich B et al), 2022 update
- The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitisRheumatology (Oxford) (Biddle K et al), 2025
- KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Disease Improving Global Outcomes, 2024
- Wechsler ME et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis (MIRRA). N Engl J Med 2017;376:1921-32New England Journal of Medicine, 2017
- Wechsler ME et al. Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis (MANDARA). N Engl J Med 2024;390:911-21New England Journal of Medicine, 2024
- Withdrawal of TAVNEOS (avacopan)AU/NZTherapeutic Goods Administration, 16 October 2026
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback